AQP7 Inhibitors

AQP7 inhibitors are a group of compounds that might reduce the activity of AQP7 through indirect modulation of cellular pathways. These inhibitors typically do not interact with AQP7 directly but may affect the cellular environment that regulates AQP7's expression and function. For example, heavy metals like mercury chloride and silver nitrate could bind to the protein and alter its structure, decreasing its glycerol transport capacity. Flavonoids like phloretin are known to inhibit a broad range of aquaporins and could similarly decrease AQP7 activity.

Inhibitors of cellular signaling pathways that indirectly affect AQP7 expression, such as genistein, could lead to downregulation of AQP7 by altering upstream kinase signaling. Similarly, pharmaceutical agents like propranolol and lovastatin might influence lipid metabolism in a way that impacts AQP7 expression or activity. Furthermore, compounds that influence glucose metabolism, such as 2-NBDG, could alter the cellular energy state and indirectly affect the expression of glycerol channels like AQP7. Sulfonylureas and glibenclamide, which modulate insulin secretion and signaling, may also have off-target effects that include the inhibition of AQP7 function.